Mycophenolate mofetil and myasthenia gravis
Author:
- 1 January 2005
- journal article
- Published by SAGE Publications in Lupus
- Vol. 14 (1_suppl) , 46-49
Abstract
Myasthenia gravis (MG) represents the prototypic autoimmune disorder with well characterized immunopathology. Advances in the diagnosis and treatment of this neuromuscular transmission disorder have significantly improved the management of myasthenic patients. Unfortunately the currently available immunomodulating treatments have significant side effects and some patients do not tolerate them or adequately respond to them. Therefore the possibility of a new immunosuppressant agent that is safe, effective and has steroid-sparing effect is very appealing. Mycophenolate mofetil (MMF) has shown promising effects in MG patients in preliminary studies and is currently being studied in two prospective, randomized, double-blind, placebo controlled, multicenter trials to better establish its role in the treatment of MG. Lupus (2005) 14, s46-s49.Keywords
This publication has 17 references indexed in Scilit:
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Myasthenia gravisNeurology, 2000
- A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravisNeurology, 1998
- Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravisAnnals of Neurology, 1997
- Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravisNeurology, 1988
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisNew England Journal of Medicine, 1987
- Azathioprine toxicity in neuromuscular diseaseNeurology, 1986
- Azathioprine in the treatment of myasthenia gravisAnnals of Neurology, 1984
- Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 PatientsAnnals of Neurology, 1984